The SF3B1 inhibitor E7107 in combination with Bcl-xL/Bcl-2 inhibitors enhances cytotoxicity to cancer cells based on the evidence that E7107 alters splicing of MCL1, but not that of BCL2L1 [16]. Here, MCL1 is linked to cancer.